Conyers Dill & Pearman advised Urovant Sciences Ltd. (“Urovant”) on its initial public offering of 10,000,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of US$140 million. Urovant has granted the underwriters a 30-day option to purchase up to 1,500,000 additional common shares at the initial public offering price, less the underwriting discounts and commissions.

Urovant is a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions.

Director Neil Henderson and Associate Robert Alexander of Conyers’ Bermuda office advised on the matter.

Stay current with our latest legal insights and subscribe today